Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STIM 
Neuronetics Inc (STIM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: STIM (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 1 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 164.87% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 191.10M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 4 | Beta 1.17 | 52 Weeks Range 0.52 - 5.92 | Updated Date 10/14/2025 |
52 Weeks Range 0.52 - 5.92 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -43.92% | Operating Margin (TTM) -21.15% |
Management Effectiveness
Return on Assets (TTM) -20.34% | Return on Equity (TTM) -190.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 246065269 | Price to Sales(TTM) 1.72 |
Enterprise Value 246065269 | Price to Sales(TTM) 1.72 | ||
Enterprise Value to Revenue 2.21 | Enterprise Value to EBITDA -2.02 | Shares Outstanding 66124820 | Shares Floating 40965648 |
Shares Outstanding 66124820 | Shares Floating 40965648 | ||
Percent Insiders 9.44 | Percent Institutions 59.07 |
Upturn AI SWOT
Neuronetics Inc
Company Overview
History and Background
Neuronetics, Inc. was founded in 2003. It focuses on developing and commercializing non-invasive neurostimulation technology for patients suffering from neurological and psychiatric disorders.
Core Business Areas
- NeuroStar TMS Therapy System: The core product is the NeuroStar TMS Therapy System, a non-invasive transcranial magnetic stimulation (TMS) therapy for treating major depressive disorder (MDD).
Leadership and Structure
The leadership team consists of key executives overseeing operations, sales, marketing, and research & development. The organizational structure is typical of a medical device company, with departments dedicated to manufacturing, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- NeuroStar TMS Therapy System: The NeuroStar TMS Therapy System is used to treat major depressive disorder (MDD). Market share data is difficult to obtain precisely but Neuronetics is a leading provider of TMS therapy for depression. Competitors include Brainsway (BWAY), Magstim, and other TMS system manufacturers. Neuronetics derived the majority of its revenues from Neurostar. The market is expanding.
Market Dynamics
Industry Overview
The neuromodulation industry is growing, driven by increasing awareness of mental health disorders and the demand for non-pharmacological treatment options. Technological advancements are making TMS more accessible and effective.
Positioning
Neuronetics is positioned as a leader in TMS therapy for depression, focusing on clinical evidence and patient outcomes to differentiate its NeuroStar system. The company is focused on expanding access and reducing the stigma associated with mental health treatments.
Total Addressable Market (TAM)
The TAM for depression treatment is substantial, encompassing millions of patients globally. Neuronetics is positioned to capture a portion of this market through its NeuroStar system, focusing on patients who have not responded to traditional antidepressant medications.
Upturn SWOT Analysis
Strengths
- FDA-cleared TMS therapy system
- Strong brand recognition in the TMS market
- Extensive clinical evidence supporting efficacy
- Established network of treatment centers
Weaknesses
- High cost of TMS therapy
- Limited reimbursement coverage in some regions
- Dependence on a single core product
- Requires trained professionals to administer
Opportunities
- Expanding reimbursement coverage
- Developing new applications for TMS therapy
- Entering new geographic markets
- Partnering with healthcare providers and insurers
Threats
- Competition from other TMS systems and alternative treatments
- Changes in reimbursement policies
- Technological obsolescence
- Economic downturn impacting patient affordability
Competitors and Market Share
Key Competitors
- BWAY
- STIM
Competitive Landscape
Neuronetics faces competition from other TMS system manufacturers and alternative depression treatments. Its competitive advantages include its established brand, clinical evidence, and network of treatment centers. A disadvantage is its single product line.
Growth Trajectory and Initiatives
Historical Growth: Neuronetics has experienced revenue growth, driven by increased adoption of NeuroStar TMS therapy.
Future Projections: Future growth projections depend on expanding access to TMS therapy, securing reimbursement coverage, and developing new applications for the technology.
Recent Initiatives: Recent strategic initiatives include expanding sales and marketing efforts, partnering with healthcare providers, and conducting clinical trials to support new indications for NeuroStar TMS therapy.
Summary
Neuronetics is a neuromodulation company focused on treating depression with TMS. It is a leader in the TMS market with a strong brand and clinical support. However, high costs and limited reimbursement pose challenges. Future growth hinges on expanding market access and innovation within the space. The company is showing revenue growth but needs to reach profitability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Neuronetics' SEC filings
- Company website
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data and financial information are subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuronetics Inc
Exchange NASDAQ | Headquaters Malvern, PA, United States | ||
IPO Launch date 2018-06-28 | President, CEO & Director Mr. Keith J. Sullivan | ||
Sector Healthcare | Industry Medical Devices | Full time employees 716 | Website https://neurostar.com |
Full time employees 716 | Website https://neurostar.com | ||
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.